PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ijpsychHomeCurrent issueInstructionsSubmit article
 
Indian J Psychiatry. 2001 Jul-Sep; 43(3): 257–263.
PMCID: PMC2956152
OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA : AN OPEN LABEL COMPARATIVE CLINICAL TRIAL FROM NORTH INDIA
Ajit Avasthi,* Parmanand Kulhara, and Neeraj Kakkar
*AJIT AVASTHI, MD., Additional Professor, Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh-160012.
PARMANAND KULHARA, MD., FRC Psych, FAMS., Professor & Head, Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh-160012.
NEERAJ KAKKAR, Ph.D., Research Associate, Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh-160012.
*Correspondence:medinst/at/pgi.chd.nic.in
Abstract
The aim of the present study was to assess the efficacy and safety of olanzapine in the treatment of schizophrenic patients. 27 patients were randomly assigned to treatment with olanzapine or haloperidol over 12 weeks. The primary efficacy measure was the mean change from baseline to endpoint in total scores on the Brief Psychiatric Rating Scale (BPRS) and assessing treatment emergent adverse events. Secondary measures were positive symptoms, negative symptoms, general psychopathology depression, anxiety and quality of life. Compared to haloperidol, olanzapine had equal effect in improving overall psychopathology, positive symptoms, and severity of schizophrenic illness. Olanzapine showed supehor improvement on negative symptoms and secondary depressive features. Commonest side effects were weight gain, sleepiness and increased duration of sleep. Olanzapine is effective in improving overall psychopathology including positive symptoms, negative and secondary depressive features in Indian patients with schizophrenia and it is safe and well tolerated at dosage between 5 to 20 mg/day
Full Text
The Full Text of this article is available as a PDF (304K).
Articles from Indian Journal of Psychiatry are provided here courtesy of
Medknow Publications